Will my processor freeze my peptide business?
- Most peptide freezes come from chargeback ratio, sudden volume spikes, or a mismatch between your site and your underwriting file.
- The warning signs almost always show up before the freeze — reserves rising, payouts slowing, documentation requests.
- You cannot make freeze risk zero, but you can move from a fragile single account to a structure that survives one acquirer pausing you.
On this page
It is 2am and you are refreshing your payout dashboard for the fourth time, because a friend in the peptide space just got terminated and now you cannot stop wondering if you are next. The order volume is good. The reviews are good. And somehow that makes it scarier, because you have heard the freeze emails arrive on the best months, not the worst ones.
So let us answer the question directly. Yes, your processor can freeze your peptide business. No, it is not random. There are specific triggers, they almost always show up with warning signs first, and most of them are things you can read off your own dashboard this week. Here is what actually causes it and what you can do about it.
Why peptide accounts get frozen
Strip away the anxiety and there are really four causes. Almost every freeze we have seen traces back to one of these.
1. Chargeback ratio crossed a line
This is the big one. The card networks set hard ceilings. Visa flags excessive at 0.9% under VAMP; Mastercard at 1.0% under ECM; severe tiers sit around 1.8-2.0%. Most acquirers pause you well before the network ceiling — some at 0.5%, some at 1.2%. If your chargeback ratio is climbing month over month, the freeze is a question of when, not if.
2. Volume spiked faster than your file allows
You got approved for one volume band and a viral month tripled it. To a risk model, a sudden 3x is indistinguishable from a bust-out. Even clean volume gets reviewed when it jumps past the band you were underwritten for.
3. Your site stopped matching your underwriting file
You added a SARM line, changed your disclaimers, or started running an aggressive subscription funnel. Acquirers re-read your site. If what they see no longer matches what they approved, that triggers a review. See what they check in our underwriting breakdown.
4. Portfolio concentration in the acquirer's eyes
Even with clean numbers, an acquirer can decide they are holding too much peptide exposure and trim the book. This one is not about you doing anything wrong, which is exactly why a single-account structure is fragile.
The warning signs come first
Freezes feel sudden but they rarely are. The account usually tells you for weeks. Watch for these:
- Your rolling reserve percentage quietly went up at renewal.
- Payouts shifted from T+1 to T+2 or longer with no explanation.
- You got a documentation request — statements, fulfillment proof, website screenshots.
- A batch got held for manual review for the first time.
- Your dispute rate ticked up two months running.
None of these guarantees a freeze. All of them mean the risk team is looking. Treat any one as a prompt to act, not a coincidence.
What raises your odds the most
Some operators are far more likely to get frozen than others. The high-risk profile, ranked by how much each factor matters:
| Risk factor | Freeze impact | Fix difficulty |
|---|---|---|
| Chargeback ratio over 1% | Very high | Hard — takes months |
| Processing on Stripe/Square | Very high | Easy — they ban peptides anyway |
| Site contradicts underwriting file | High | Easy — fix the site |
| 3x+ unannounced volume spike | High | Medium — pre-warn acquirer |
| Single MID, no failover | Medium | Medium — restructure |
| Thin refund/COA documentation | Medium | Easy — publish it |
If you are on Stripe, Square, PayPal, or Shopify Payments, the answer is not "maybe" — those acquirers decline peptides per policy and close operators who slip through, usually within 3-6 months. That is the first thing to fix.
What you can do this week
You cannot drive freeze risk to zero, but you can move a long way off the fragile end. In order of impact:
- Get your chargeback ratio under control. Tighten refund policy, file representment on every dispute, and add delivery confirmation. This is the single highest-leverage move.
- Make your site match your file. Align disclaimers, SKU labels, and funnel claims with what your acquirer approved. Use the compliance checklist.
- Pre-warn your acquirer before a big push. A heads-up email before a launch turns a scary spike into expected volume.
- Get off processors that ban peptides. Move to a peptide-friendly acquirer through Authorize.net or NMI.
What happens in the first hours of a freeze
Knowing the mechanics takes some of the fear out of it. A freeze is rarely the dramatic event it feels like at 2am. It usually arrives as one of three things, and which one you got determines everything about your next move.
- Funds hold with a reserve. The acquirer holds funds for an extended review — often 90-180 days on the held portion — but you may keep processing. The least severe version, and frequently resolvable if you respond to documentation requests cleanly and on time.
- Processing paused, funds held. No new charges clear and existing funds are held, but the account still exists in a suspended state. Recoverable in some cases, not others.
- Closed for cause. Full termination, sometimes with a MATCH entry attached. The MATCH list is run by Mastercard, carries a five-year retention, and uses fourteen reason codes. This is the least recoverable outcome and the one to structure against in advance.
The single worst move in any of these is to panic-open a second account under the same principal to keep processing. Acquirers link accounts by principal, banking, and device, and a second account opened in the middle of a freeze tends to get closed as linked — turning one problem into two. If a freeze does land, the full step-by-step is in the 48-hour playbook.
The structural answer
Everything above lowers the odds of a freeze. None of it changes what happens when one lands anyway. A single peptide brand on a single MID has one point of failure — that account freezes and the business stops. That is the real source of the 2am dread.
Operators running three or more peptide brands can restructure so one acquirer pausing a brand does not take down the portfolio. A parent account with per-brand descriptors and failover routing means a freeze on one brand routes around instead of killing revenue. We do not process your payments — we orchestrate the acquirers underneath. It is not right for a single-brand operator, but for a portfolio it converts a business-ending event into an operational one. See how the orchestration works and the peptide operator playbook.
So, will you get frozen?
If your ratio is clean, your site matches your file, you are on a peptide-friendly acquirer, and you do not surprise them with volume — your odds are low. If any of those are off, fix them this week. And if you are running multiple brands and the single-account fragility is what keeps you up, that is worth a conversation.
We talk to peptide operators at exactly this stage of worry every week. Bring your brand count, your ratio, and your monthly volume, and we will give you an honest read on where your real risk is — even if the answer is "stay where you are and fix your refund policy." Start the application: twelve questions, no hard pull, a straight answer inside 48 hours.